Stull, Stull & Brody Announces Class Action
on Behalf of Shareholders of Sanofi-Aventis

NEW YORK, November 14, 2007 — Attorney Advertising. Notice is hereby given that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Sanofi-Aventis (“Sanofi” or the “Company”) (NYSE:SNY) publicly traded stock or American Depository Receipts (“ADRs”) between February 17, 2006 and June 13, 2007 (the “Class Period”).

Stull, Stull & Brody has substantial experience representing employees who suffered losses from purchases of their employer’s stock in their 401(k) plans. If you bought Sanofi stock through your Sanofi retirement account and have information or would like to learn more about these claims, please contact us.

The complaint charges Sanofi and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide. Sanofi is the third largest pharmaceutical company in the world. According to the complaint, in 2002, Sanofi began testing a new drug, Zimulti, which is designed to fight obesity by reducing appetite. As the first drug of its class, Zimulti was projected to become extremely profitable for Sanofi. Sanofi submitted its New Drug Application (“NDA”) for Zimulti in April 2005 and on June 23, 2005, the Company announced that the Food and Drug Administration (“FDA”) had accepted it for filing. The complaint alleges that defendants’ statements regarding Zimulti were materially false and misleading when made because defendants concealed data concerning Zimulti’s propensity to cause depression. On June 13, 2007, the committee met and made a unanimous decision that Zimulti could not be recommended for approval. After the FDA’s decision on June 13, 207, Sanofi’s securities declined $1.87, or 4.16%, closing at $43.07 on heavy trading volume.

Plaintiff seeks to recover damages on behalf of all those who purchased or otherwise acquired Sanofi publicly traded stock or ADRs during the Class Period, which is between February 17, 2006 and June 13, 2007. If you purchased or otherwise acquired Sanofi publicly trade stock or ADRs during the Class Period, and either lost money on the transaction or still hold the securities, you may wish to join in the action to serve as lead plaintiff. If you purchased Sanofi publicly traded stock or ADRs during the Class Period, you may request that the Court appoint you as lead plaintiff no later than 60 days from November 13, 2007.

A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as “lead plaintiff.” Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Stull, Stull & Brody, or other counsel of your choice, to serve as your counsel in this action. Stull, Stull & Brody has litigated many class actions for violations of securities laws in federal courts over the past 30 years and has obtained court approval of substantial settlements on numerous occasions. Stull, Stull & Brody maintains offices in New York and Los Angeles.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Tzivia Brody, Esq. at Stull, Stull & Brody by e-mail at SSBNY@aol.com, by calling toll-free 1-800-337-4983, or by fax at 212/490-2022, or by writing to Stull, Stull & Brody, 6 East 45th Street, New York, NY 10017. You can also visit our website at www.ssbny.com.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.

© Copyright 1999-2005. Stull, Stull & Brody
Published in U.S.A. All rights reserved.
Reproduction/redistribution prohibited.